JCR Pharmaceuticals Secures Kuwait Approval for Hunter Syndrome Therapy IZCARGO

JCR Pharmaceuticals Co., Ltd., a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, announced that IZCARGO™ (pabinafusp alfa, or JR-141), a blood-brain barrier-penetrating enzyme replacement therapy (ERT) for Hunter syndrome developed using JCR’s proprietary J-Brain Cargo® technology, received conditional marketing authorization in Kuwait.

Kuwait is the second market outside Japan where IZCARGO™ has received approval, following the United Arab Emirates in July 2026. IZCARGO™ was approved and launched in Japan in 2021 and is currently being evaluated in an ongoing global Phase III clinical trial.

JCR has been working to expand access to IZCARGO™ outside of Japan while advancing its global clinical development program. As part of this effort, JCR entered into a marketing and distribution agreement with Taiba Middle East FZ LLC (“Taiba”) and pursued regulatory approval in Kuwait based on the product’s marketing authorization in Japan. Under this agreement, JCR will also seek marketing authorization for IZCARGO™ in countries across the Middle East and North Africa (MENA) region, while Taiba will be responsible for sales and distribution in the relevant territories.

“The approval of IZCARGO™ in Kuwait marks an important advancement in our efforts to broaden access to specialized treatments for rare diseases in the region,” said Dr. Saif Al Hasani, Taiba Group CEO. "Building on the UAE approval, this milestone highlights the value of strong partnerships between regional healthcare organizations and global innovators in translating medical advancements into meaningful progress for patients. At Taiba, we remain focused on supporting sustainable access to innovative therapies and strengthening the region’s capacity to address complex and underserved medical needs.”

Source: JCR Pharmaceuticals Co., Ltd.